MasTec Inc (MTZ)vsSanofi ADR (SNY)
MTZ
MasTec Inc
$363.89
-2.89%
INDUSTRIALS · Cap: $28.68B
SNY
Sanofi ADR
$44.38
+4.74%
HEALTHCARE · Cap: $104.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 210% more annual revenue ($47.35B vs $15.28B). SNY leads profitability with a 16.0% profit margin vs 3.0%. MTZ appears more attractively valued with a PEG of 1.64. MTZ earns a higher WallStSmart Score of 63/100 (C+).
MTZ
Buy63
out of 100
Grade: C+
SNY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MTZ.
Margin of Safety
+5.5%
Fair Value
$49.78
Current Price
$44.38
$5.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.5% year-over-year
Earnings expanding 508.0% YoY
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Areas to Watch
Expensive relative to growth rate
Trading at 8.6x book value
3.0% margin — thin
Operating margin of 3.7%
Expensive relative to growth rate
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : MTZ
The strongest argument for MTZ centers on Revenue Growth, EPS Growth. Revenue growth of 34.5% demonstrates continued momentum.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Debt/Equity. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bear Case : MTZ
The primary concerns for MTZ are PEG Ratio, Price/Book, Profit Margin. A P/E of 63.7x leaves little room for execution misses. Thin 3.0% margins leave little buffer for downturns.
Bear Case : SNY
The primary concerns for SNY are PEG Ratio, EPS Growth.
Key Dynamics to Monitor
MTZ profiles as a hypergrowth stock while SNY is a mature play — different risk/reward profiles.
MTZ carries more volatility with a beta of 1.79 — expect wider price swings.
MTZ is growing revenue faster at 34.5% — sustainability is the question.
SNY generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
MTZ scores higher overall (63/100 vs 51/100) and 34.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MasTec Inc
INDUSTRIALS · ENGINEERING & CONSTRUCTION · USA
MasTec, Inc., an infrastructure construction company, provides engineering, construction, installation, maintenance, and upgrade services for communications, energy, utilities, and other infrastructure primarily in the United States and Canada. The company is headquartered in Coral Gables, Florida.
Visit Website →Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other ENGINEERING & CONSTRUCTION Stocks
Want to dig deeper into these stocks?